亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

浙江臺州市保隆化工有限公司  

抗腫瘤產品,醋酸格拉替雷

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:董女士
  • 電話:86-0576-88702852
  • 郵件:eric@bolonpharm.com
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 醋酸格拉替雷中間體2224-52-4
醋酸格拉替雷中間體2224-52-4
單價 面議對比
詢價 暫無
發貨 浙江付款后3天內
過期 長期有效
更新 2014-03-12 14:28
 
詳細信息

中文名稱:

(S)-4-甲基唑烷-2,5-二酮

中文同義詞:

(S)-4-甲基唑烷-2,5-二酮;(S)-4-甲基惡唑烷-2,5-二酮;(S)-4-甲基惡唑-2,5-二酮;ALA-NCA

英文名稱:

(S)-4-METHYL-2,5-OXAZOLIDINEDIONE

英文同義詞:

(S)-4-METHYL-OXAZOLIDINE-2,5-DIONE;(S)-4-METHYL-2,5-OXAZOLIDINEDIONE;(S)-4-Methyl-2,5-oxazolidonedione;H-ALA-NCA;Alanine, NCA;N-Carboxy-L-alanine anhydride;4-methyl-1,3-oxazolidine-2,5-dione;4-methyloxazolidine-2,5-quinone

CAS:

2224-52-4

分子式:

C4H5NO3

分子量:

115.09

EINECS:

218-750-4

Mol文件:

2224-52-4.mol

 

 

©2025 浙江臺州市保隆化工有限公司 版權所有   技術支持:化工網   訪問量:4591  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |